Vincenzo Formica, MD, Specialist in Oncology and PhD in Experimental Physiopathology, is currently Chief Doctor at the Medical Oncology Unit, Tor Vergata University Hospital and Researcher at the Internal Medicine Department of the University of Rome Tor Vergata. Dr. Formica participates as Principal Investigator (PI) and/or co-investigator to several clinical projects, sponsored and granted either by Government Institutions or private Companies. Among the projects of interest: Pharmacological Modulation, In Vivo and In Vitro, of Tumour Antigens: a Tool to improve Cancer Diagnosis and Cancer Therapy Professional skills: performance of several molecular techniques (Real Time-PCR, Western Blot, Norther Blot, Cell Cultures); Gastrointestinal Stromal tumors (Investigator in ”Phase III, Randomized, Double Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients with Imatinib Mesylate (Gleevec, Glivec®)-Resistant or Intolerant Malignant Gastrointestinal Stromal Tumor”); Neuroendocrine tumors (Investigator in ”CROMaNET: Observational study to evaluate Chromogranin A as a marker for diagnosis and follow-up of NET therapy”); Phase I and New Drugs Development in solid tumors. Relationship between cancer and thromboembolic events; Breast Cancer care; Lymphomas. Colorectal cancer. Dr. Formica has been also actively involved in clinical and translational studies – performed according to Good Clinical Practice.